En español In English Contact Us
 
 
 
 
 

Pulmonary Arterial Hypertension (PAH)

Accredo is one of the largest national pharmacy networks with clinical teams dedicated to the treatment of pulmonary arterial hypertension. We are the only national provider of all available FDA-approved therapies for PAH. Our dedication to patient service has led to exclusive relationships with GlaxoSmithKline, provider of Flolan®, and Actelion, provider of Veletri®. No other specialty pharmacy has access to these front-line therapies.

Pulmonary arterial hypertension therapies available from Accredo:

Infused therapies


• Epoprostenol sodium (generic)
• Flolan® (epoprostenol sodium) www.flolan.com
• Remodulin® (treprostinil) www.remodulin.com
• Veletri ® (epoprostenol for injection) www.veletri.com

Inhaled therapies


• Ventavis® (iloprost) www.4ventavis.com
• Tyvaso® (treprostinil) www.tyvaso.com

Oral therapies

• Adcirca® (tadalafil) www.adcirca.com
• Adempas® (riociguat) www.adempas.com
• Letairis® (ambrisentan) www.letairis.com
• Opsumit® (macitentan) www.opsumit.com
• Orenitram® (treprostinil) www.orenitram.com
• Revatio® (sildenafil) www.revatio.com
• Sildenafil (generic)
• Tracleer® (bosentan) www.tracleer.com
• Uptravi® (selexipag) www.uptravi.com

Patients receive services designed to meet their unique PAH therapy needs:

• Experienced clinicians
• An extensive network of pharmacies
• A national customer support center
• Specific support programs
• Reimbursement specialists

If you have questions or need more information regarding PAH therapy management services, please call 1 866 FIGHT-PH (1 866 344-4874).

What is PAH? 1 
Pulmonary hypertension is a rare blood vessel disorder of the lung in which the pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs) rises above normal levels and may become life-threatening.

Symptoms of pulmonary hypertension include shortness of breath with minimal exertion, fatigue, chest pain, dizzy spells, and fainting. When pulmonary hypertension occurs in the absence of a known cause, it is referred to as idiopathic pulmonary arterial hypertension (IPAH). There are likely many unknown causes of IPAH. IPAH is extremely rare, occurring in about two persons per million population per year.

Secondary pulmonary hypertension means the cause is known. Common causes of secondary PH are the breathing disorders emphysema and bronchitis. Other less frequent causes include inflammatory or collagen vascular diseases, such as scleroderma, CREST syndrome, or systemic lupus erythematosus (SLE). Congenital heart diseases that cause shunting of extra blood through the lungs—like ventricular and atrial septal defects, chronic pulmonary thromboembolism (old blood clots in the pulmonary artery), HIV infection, liver disease, and diet drugs like fenfluramine and dexfenfluramine—are also causes of pulmonary hypertension.



1. Pulmonary Hypertension Association. What is PH? Available at:http://www.phassociation.org/Page.aspx?pid=429. Accessed June 28, 2010.

All rights in the product names of all third-party products listed on this website, whether or not appearing with the trademark symbol, belong exclusively to their respective owners.


 

Share this page

CloseClose